Strides Pharma obtains FDA green light for potassium chloride
Potassium chloride oral solution had a market value of $56 million, according to IQVIA January 2021 data.
Strides Pharma Science’s subsidiary, Strides Pharma Global Private Limited, Singapore, has received the Food and Drug Administration’s approval for potassium chloride oral solution, 20 mEq.
The medication is used for the treatment of Hypokalaemia with or without metabolic alkalosis in patients for whom, dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
The product is the generic of Pharma Research Software Solutions’ potassium chloride oral solution. It will be manufactured at Strides’ facility in Bengaluru.
Potassium chloride oral solution had a market value of $56 million, according to IQVIA January 2021 data.